Other Services

EMMAA Bob with Bioagents

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP22 deubiquitinates CD274. 6 / 6

1 | 5

reach

"In addition, USP22 could inhibit the ubiquitination of PD-L1 protein."

35583065

reach

"USP22 deubiquitinated PD-L1 and inhibited its proteasome degradation."

32665011

reach

"USP22 deubiquitinates CD274 to suppress anti-cancer immunity."

31399419

reach

"However, our previous study demonstrated that USP22 induces the deubiquitination of PD-L1 and prevents PD-L1 degradation."

32850399

reach

"USP22 can deubiquitinate PD-L1 itself or CSN5 for their stabilization [233] (Figure 3)."

| PMC

ubibrowser

"Here, we identified ubiquitin-specific protease 22 (USP22) as a novel deubiquitinase of CD274."

31399419

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Databases

Reading